Pulse Biosciences Announces Collaboration with CardioNXT for nsPFA First-in-Human Atrial Fibrillation Study

Collaboration with CardioNXT provides navigation and mapping system integration with Pulse Biosciences’ nsPFA circumferential catheter to support first-in-human treatments

Excerpt from the Press Release:

HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced a collaboration with CardioNXT, to support Pulse Biosciences’ planned nsPFA cardiac catheter first-in-human study focused on the treatment of atrial fibrillation.

“We are excited to announce this collaboration and the progress we’ve made integrating our circumferential nsPFA catheter with the CardioNXT iMap System,” said Kevin Danahy, Chief Executive Officer of Pulse Biosciences. “The CardioNXT navigation and mapping system was our top choice for integration with our novel nsPFA cardiac circumferential catheter. Their iMap system offers dynamic referencing to provide superior accuracy and stability when navigating our catheter to targeted tissue areas. We’re on track to initiate our first-in-human study in the first half of next year and believe this combination has the potential to achieve best-in-class clinical outcomes.”

The collaboration will include full integration of Pulse Biosciences’ nsPFA circumferential cardiac catheter and CardioNXT’s iMap Navigation and Mapping System, enabling electrophysiologists to successfully visualize individual cardiac structures and place the nsPFA catheter for circumferential ablations of targeted pulmonary veins in the treatment of atrial fibrillation.

Click the button below to read the entire Press Release:

Continue Reading The Press Release